Flavonoids are polyphenolic compounds built on a C6-C3-C6 carbon skeleton, subdivided into subclasses such as flavones, flavonols, flavanones, flavanols, isoflavones and anthocyanins depending on the arrangement of rings and chemical substituents. Each subclass occupies a distinct niche in the food supply. Citrus fruits deliver flavanones like naringin and naringenin; apples, plums and cherries supply flavanols; berries, red cabbage and eggplant are dense with anthocyanins; onions, broccoli and kale provide flavonols such as quercetin and kaempferol; and soybeans and chickpeas are the principal dietary sources of isoflavones like genistein and daidzein. Tea, coffee, cocoa and red wine contribute further to daily intake, while herbs and traditional medicinal plants such as Eucommia ulmoides and hawthorn concentrate these molecules to remarkable levels.

The biological activities of these compounds read like a checklist of PCOS pathology. Flavonoids scavenge reactive oxygen species, dampen inflammatory signaling, regulate glucose and lipid metabolism and improve insulin sensitivity. In experimental models, two molecules in particular have drawn attention. Luteolin normalized the estrous cycle and ovarian morphology in animal studies while restoring activity of the Nrf2 antioxidant pathway and its downstream genes. Quercetin regulated the ratio of luteinizing hormone to follicle-stimulating hormone, adjusted estrogen levels and reduced cholesterol, acting on the pituitary-ovarian axis in ways the authors suggest could one day translate to human therapy.

The molecular logic is intricate. Hyperandrogenism, the excess of male hormones that drives many PCOS symptoms, depends on enzymes such as CYP17A1 in ovarian theca cells. Quercetin’s ortho-dihydroxyl groups allow it to bind PI3K proteins and reduce CYP17A1 expression, curbing the conversion of progesterone to androgens. Soy isoflavones suppress testosterone production by inhibiting 3β-hydroxysteroid dehydrogenase and 17β-hydroxysteroid dehydrogenase in ovarian interstitial cells. Other flavonoids boost aromatase activity in granulosa cells, improving the conversion of androgens to estradiol and helping rebalance the LH/FSH ratio that governs ovulation.

On the metabolic front, flavonoids confront the insulin resistance that afflicts many women with PCOS and feeds a vicious cycle with hyperandrogenism. Quercetin activates the AMPKα subunit in fat cells and promotes the translocation of the GLUT4 glucose transporter to the cell membrane, enhancing glucose uptake. Flavonoids also block NF-κB and MAPK inflammatory cascades, lowering production of tumor necrosis factor-α and interleukin-6, and they induce antioxidant enzymes such as superoxide dismutase and glutathione peroxidase through the Nrf2 transcription factor. In animal models, these effects reduced cystic follicles, increased mature follicles and improved ovulation and conception rates, while protecting oocyte membranes and mitochondria from oxidative damage.

There is, however, a formidable catch: bioavailability. Most flavonoids are poorly absorbed, extensively modified by gut bacteria and liver enzymes, and rapidly excreted. Urinary excretion studies show that only 2.5 to 40 percent of dietary kaempferol and quercetin is recovered. The clinical trials that have shown promise typically used high-dose extracts of several hundred milligrams per day, whereas Western diets deliver an average of just 20 to 50 milligrams daily. This dose gap, the review argues, is the central contradiction in translating flavonoid science to the public: the question is not whether these compounds work, but how to achieve effective exposure through food.

Food engineering offers partial answers. Microencapsulation wraps flavonoid extracts in protective matrices like maltodextrin or whey protein, shielding them from light, oxygen, heat and stomach acid until they reach the intestine. Nano-encapsulation, using particles smaller than 200 nanometers such as nanostructured lipid carriers and nanoemulsions, exploits intercellular transport pathways in the gut lining; quercetin delivered this way achieved a 3.2-fold increase in oral bioavailability in animal studies. Liposomal carriers form mixed micelles that improve dispersion of fat-soluble aglycones, while enzymatic hydrolysis with β-glucosidase and fermentation with lactic acid bacteria strip sugar groups from flavonoid glycosides, converting them into more absorbable forms. Fermented soy milk and Pu’er tea are cited as successful commercial examples of this principle. Even simple food pairings help: black pepper’s piperine inhibits UGT enzymes and reduces first-pass metabolism, and modest amounts of dietary fat promote micellization of fat-soluble flavonoids.

Sensory and stability challenges remain significant engineering hurdles. Anthocyanins fade rapidly at neutral or alkaline pH, flavanols succumb to enzymatic oxidation, and flavonoids generally impart bitterness and astringency that can sink consumer acceptance. The review describes countermeasures ranging from acidified formulations and blanching to cyclodextrin inclusion and flavor masking with sweeteners like vanillin. It also sketches practical daily menus for women with PCOS: soy milk with blueberries at breakfast, onion salad with broccoli at lunch, green tea in place of afternoon coffee, and citrus fruit after dinner, with olive oil or nuts paired to boost absorption and a pinch of black pepper to extend systemic exposure.

Perhaps the most forward-looking section addresses personalization. PCOS is not one disease but a spectrum of metabolic phenotypes, and the authors propose matching flavonoid formulas accordingly: quercetin and EGCG for insulin-resistant patients, soy isoflavones for those with prominent hyperandrogenism, and anthocyanins or hawthorn leaf flavonoids for inflammation-dominant cases. Genetic polymorphisms in UGT, COMT and CYP450 enzymes, along with individual gut microbiome composition, could eventually predict who responds best to which compounds, supported by artificial intelligence screening of synergistic combinations and multi-omics mapping of flavonoid targets.

The authors are careful to note the limits of current evidence. Most clinical trials to date have been small, short, single-center studies delivering flavonoids as capsules rather than foods, and the 2023 international PCOS guidelines still stop short of recommending specific dietary patterns or micronutrient supplementation. Rigorous, multicenter, long-duration trials with standardized dietary background controls and adherence tracking are needed before flavonoid-enriched functional foods can earn regulatory approval or health claims. Yet the framework laid out — from biochemical mechanism through food processing technology to phenotype-matched dietary plans — represents an unusually complete translational roadmap. If it succeeds, the management of one of the most common endocrine disorders in women may begin not in the clinic, but in the grocery aisle.

Subject of Research: Plant flavonoids as dietary interventions for polycystic ovary syndrome

Article Title: Plant Flavonoid—Enriched Functional Foods for Polycystic Ovary Syndrome: Dietary Sources, Bioavailability Enhancement, and Personalized Intervention Strategies

Article References: Wang, J., Zhu, H., Shen, Q., Zhong, Y., Du, Y., Yu, W., Mao, F., Yao, Z., Zhu, W., Sun, L., Lin, Q., Xu, X., & Zhu, J. (2026). Plant Flavonoid—Enriched Functional Foods for Polycystic Ovary Syndrome: Dietary Sources, Bioavailability Enhancement, and Personalized Intervention Strategies. Food Science & Nutrition, 14(9), Article e72350. https://doi.org/10.1002/fsn3.72350

Image Credits: AI Generated

DOI: 10.1002/fsn3.72350

Keywords: PCOS, flavonoids, functional foods, quercetin, isoflavones, bioavailability, insulin resistance, hyperandrogenism, nanoencapsulation, personalized nutrition, polyphenols, ovarian health